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ABSTRACT 
Objective: A specific, simple and sensitive high-performance liquid chromatographic method for the estimation of Bedaquiline (BDQ) and 
Delamanid (DLM) in human plasma was developed.  
Methods: The method involved deproteinization and further extracted the analyte using Solid Phase Extraction (SPE) cartridge and analysed using 
C18 column with the wavelength set at 231 nm. The isocratic mobile phase consisted of 10 mmol ammonium acetate buffer containing 0.25% acetic 
acid and 0.02% trifluoroacetic acid and acetonitrile in the ratio of 20:80(v/v). The validation parameters were evaluated. The method was applied 
to estimate plasma BDQ and DLM collected from five MDR-TB patients. 
Results: Well resolved peaks of BDQ and DLM at retention times of 5.4 and 2.6 min were obtained respectively. The calibration curve was linear 
over a range of 0.01–10.0 µg/ml for both BDQ and DLM. The intra-and inter-day relative standard deviations for standards were below 10%. The 
recoveries for BDQ ranged from 101% to 107% and 98% to 107 % for DLM respectively. 
Conclusion: A specific and sensitive method for simultaneous determination of BDQ and DLM in plasma using high-performance liquid 
chromatography was developed. This method can be used in clinical studies to evaluate drug exposure. 
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INTRODUCTION 
The emergence of drug resistance is a major threat to global 
tuberculosis (TB) care and control. The crisis of MDR-TB detection 
and treatment continues. Recognizing that the treatment of pre-XDR 
and XDR-TB cases are very complex and given the urgent need to 
increase treatment success to DR-TB, careful evaluation of newer 
drugs and treatment strategies are urgently needed to build a better, 
safer, less toxic, shorter and cheaper regimen to reduce patient 
suffering and mortality. BDQ and DLM are newly approved anti-TB 
drugs and all are well tolerated. BDQ, previously known as TMC 207, 
belongs to a new class of drugs called diarylquinolines and is placed 
with anti-TB drugs belonging to Group 5, primarily because it does 
not belong to any other TB drug families. DLM is a pro-drug that 
must be reduced by the deazaflavin-dependent nitroreductase to its 
des-nitro metabolite to be active [1]. The World Health Organization 
(WHO) recommends using these new anti-TB drugs for a 
standardized duration of 24 w in patients with drug-resistant 
tuberculosis. The concomitant use of BDQ and DLM is restricted to 
patients with “no other therapeutic options”. Médecins Sans 
Frontières has supported the use of combination BDQ and DLM for 
people with few treatment options since 2016. Based on WHO 
recommendations, Phase III clinical trials are initiated with BDQ and 
DLM in pre-XDR and XDR pulmonary TB patients.  
Several analytical methods have been developed for the estimation of 
BDQ in plasma which includes high-performance liquid 
chromatography (HPLC) inductively coupled plasma (ICP), mass 
spectrometry (MS) [2, 3], tandem mass spectrometry [4, 5] and 
LCMS/MS [6]. Most of the existing methods for BDQ, however, were 
developed using LCMS/MS. Furthermore, LCMS/MS instrument is 
quite expensive and may not be possible in resource-limited settings. 
Similarly, LCMS/MS methods for the determination of DLM in plasma 
have been developed [7]. There is no simultaneous method for the 
estimation of BDQ and DLM in plasma using HPLC is available. 
Therefore, the purpose of this study was to develop a simple, sensitive 
and specific HPLC method for simultaneous estimation of plasma BDQ 
and DLM concentrations in MDR-TB patients. 
MATERIALS AND METHODS 
Pure BDQ powder was obtained from Janssen Pharmaceuticals 
(Belgium) and DLM from Otsuka Pharmaceuticals (Japan). 
Acetonitrile (Merck), orthophosphoric acid, acetic acid, dimethyl 
sulphoxide (DMSO) and trifluoroacetic acid were purchased from 
Qualigens, India. Deionized water was processed through a water 
purification system (Siemens, Germany). Pooled human plasma was 
obtained from a Blood Bank, Chennai, India. All chemicals used in 
the method were of analytical grade. 
A stock BDQ standard solution (1 mg/ml) was prepared by dissolving 
BDQ in acetonitrile. DLM stock solution was prepared separately by 
dissolving in DMSO. Working standard concentrations ranging from 
0.01 to 10 µg/ml for DLM and BDQ together were prepared in pooled 
plasma. Calibration standards for BDQ and DLM were freshly prepared 
on the first day of the validation and stored at–20 °C to carry out the 
validation parameter experiments on the other validation days. 
Samples were prepared by adding 300 µl of 4% orthophosphoric 
acid in water to 300 µl of calibration standards and test samples in 
plasma. The microcentrifuge vials were vortexed for 3 min and 
centrifuged for 10 min at 10,000 RPM. The analyte was extracted 
through solid-phase extraction cartridges (MCX 1 cc 30 mg). The 
eluted solution was evaporated to dryness. The dried residue was 
reconstituted in 100 µl of mobile phase and 30 µl was injected into 
the HPLC system. 
Chromatographic system 
The HPLC system–Prominence-i (Shimadzu Corporation, Kyoto, Japan) 
comprised of two pumps (LC-2030-3D), photodiode array detector 
(SPD-20AV) with a built-in autosampler and system controller. Data 
collection and acquisition were carried out using Lab solution 
software. Ascentis R Express C18 (15 cm X 4.6 mm ID, 2.7 µgm particle 
size (Merck, Germany) was used as the analytical column.  
An isocratic mobile phase was prepared by mixing 10 mmol 
ammonium acetate buffer containing 0.25% acetic acid and 0.02% 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                            Vol 13, Issue 6, 2021 
Hemanth et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 6, 36-40 
 
37 
trifluoroacetic acid and acetonitrile in the ratio of 20:80 (v/v). The 
solvents were degassed individually using a Millipore vacuum pump 
before preparing the mobile phase. Each chromatogram was run for 
7 min at a flow rate of 1.0 ml/min at 40 °C, with the PDA detector set 
at a wavelength of 231 nm. Unknown concentrations were 
calculated from linear regression analysis vs BDQ or DLM 
concentrations curve; linearity was verified using estimates of 
correlation coefficient (r).  
Analytical method validation 
The parameters for validation of the method developed included 
linearity, inter-and intra-day variations, accuracy and precision, 
specificity and recovery. The calibration curve for BDQ and DLM 
consists of 7 standards ranging from 0.01 µg/ml to 10.0 µg/ml. The 
intra-day and inter-day variations were evaluated by processing 
each sample containing BDQ and DLM standard concentration in 
duplicate for six consecutive days. The accuracy and linearity were 
determined by analysing a set of standard solutions with 
concentrations ranging from 0.01 to 10.0 µg/ml. In order to evaluate 
the precision of the method, plasma samples containing varying 
concentrations of BDQ and DLM were analyzed in duplicate on three 
consecutive days. 
For the recovery experiments, known concentrations of BDQ and 
DLM (0.05, 0.5, 1.0 and 5.0 µg/ml) were prepared in pooled human 
plasma and were spiked with lower and higher concentrations of 
standards. The percentage of drug recovery from plasma samples 
was calculated by dividing the difference in BDQ and DLM 
concentrations by the added concentration. Recovery experiments 
were carried out on three different occasions. 
The effect of endogenous substances was examined by analyzing 
blank plasma samples using a different batch of pooled plasma. 
Interference from certain anti-tuberculosis drugs such as rifampicin, 
isoniazid, pyrazinamide, ethambutol, streptomycin, ethionamide, 
levofloxacin and certain antiretroviral drugs, namely, nevirapine, 
efavirenz, zidovudine, didanosine, stavudine, lamivudine, saquinavir, 
lopinavir, ritonavir and indinavir at a concentration of 10 µg/ml was 
also evaluated. 
Limits of quantitation (LOQ) and detection (LOD) values were 
estimated mathematically from the standard curve equations. The 
LOQ was obtained by multiplying the standard deviation (SD) of the 
Y-axis intercepts by 10. The LOD was equal to 3.3 times the SD of the 
Y-axis intercepts [8]. 
RESULTS 
Under the chromatographic conditions described above, BDQ and DLM 
were well separated and seen as a discrete peak in the representative 
chromatograms of extracted plasma standards 10.0 and 0.01 µg/ml 
and an extracted blank plasma sample from MDR-TB patient (fig. 1A–
B) with the retention times of 5.4 and 2.6 min. Blank plasma sample 
did not give any peak at the retention times of BDQ and DLM (fig. 1C). 
In view of the potent antimycobacterial activity, BDQ and DLM are 
used in the treatment of MDR-TB along with other second-line anti-
tuberculosis drugs. It, therefore, becomes necessary to rule out the 
interference of other second-line anti-TB drugs as well as anticipated 
co-administered drugs in the assay of BDQ and DLM and establish the 
specificity of the method. No endogenous substances, first-line anti-TB 
drugs, second-line anti-TB drugs or anti-retroviral drugs interfered 
with the BDQ and DLM chromatogram. 
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Fig. 1A: Chromatogram of extracted Bedaquiline and Delamanid plasma standard 10.0 µg/ml 
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Fig. 1B: Chromatogram of extracted Bedaquiline and Delamanid plasma standard 0.01 µg/ml 
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Fig. 1C: Chromatogram of extracted blank plasma 
 
In the present method, BDQ and DLM concentrations ranging from 0.01 
to 10 µg/ml were checked for linearity. These concentrations span the 
range of clinical interest. The calibration curve parameters of BDQ and 
DLM from six individual experiments for standard concentrations 
ranging from 0.01 to 10.0 µg/ml showed a linear relationship (fig. 2A 
and 2B). The mean correlation coefficient (R), coefficient of determinants 
(R2), slope and intercept values were 0.9996, 0.9998, 61583 and-486.84 
for BDQ and 0.9999, 0.9999, 35943 and-344.63 for DLM respectively. 
 
 
Fig. 2A: Calibration curve of plasma Bedaquiline 
 
 
Fig. 2B: Calibration curve of plasma delamanid 
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The linearity and reproducibility of the various standards used 
for constructing calibration graphs for plasma BDQ and DLM are 
given in (table 1). The intra-and inter-day relative standard 
deviation (RSD) for standards containing 0.01–10.0 µg/ml 
ranged from 2.41 to 4.92 % and 2.59 to 5.35 % for BDQ and 0.76 
to 4.41 % and 2.18 to 5.99 % DLM respectively. The accuracy of 
plasma BDQ and DLM concentrations ranged from 93% to 102 
and are given in (table 2). 
  




 Mean peak height+SD(%RSD) 
Delamanid Bedaquiline 
Within day (n=5) Between day (n=5) Within day (n=5) Between day (n=5) 
10 353636+2685.57 (0.76) 365778+15866.66 (4.34) 611653+20414 (3.34) 536320+13868 (2.59) 
5 179418+7311.22 (4.07) 171708+3746.49 (2.18) 315928+11387 (3.6) 264907+10772 (4.07) 
1 33518+713.34 (2.13) 30421+1582.17 (5.2) 55756+1342 (2.41) 51281+2742 (5.35) 
0.5 16491+340.33 (2.06) 15118+462.14 (3.06) 29592+822 (2.78) 25343+709 (2.8) 
0.1 3565+100.89 (2.83) 3200+82.12 (2.57) 5764+272 (4.72) 5009+181 (3.62) 
0.05 1856+83.68 (4.51) 1689+101.26 (5.99) 3242+159 (4.92) 2553+75 (2.93) 
0.01 413+16.41 (3.97) 308+12.67 (4.12) 623+20 (3.3) 501+23 (4.66) 
SD= Standard deviation, RSD= Relative standard deviation, n = number, µg/ml = microgram per millilitre 
 
Table 2: Accuracy of plasma bedaquiline and delamanid 
Standard Delamanid Bedaquiline 
Mean (n=6) % Mean (n=6) % 
10 10.02 100 9.98 100 
5 5.11 102 5.11 102 
1 0.93 93 0.93 93 
0.5 0.47 94 0.49 98 
0.1 0.1 100 0.1 100 
0.05 0.049 98 0.051 102 
0.01 0.010 100 0.010 100 
n = number, the precision of the method was further evaluated by analysing plasma samples containing different concentrations of BDQ and DLM 
(table 3). The RSD for these samples ranged from 94 to 100 % for DLM and 97 to 102 % for BDQ respectively. 
 




Found concentration (µg/ml) mean+SD % RSD Found concentration (µg/ml) mean+SD % RSD 
10 10.03±0.18 100 10.0±0.30 100 
0.5 0.47±0.01 94 0.48±0.03 97 
0.05 0.05±0.0 96 0.051±0.01 102 
0.01 0.01±0.0 100 0.01±0.0 100 
SD = Standard deviation, RSD = Relative standard deviation, n = number, µg/ml = microgram per millilitre 
 
The LOD and LOQ were estimated mathematically from the standard 
curve equation and were 0.005 and 0.01µgg/ml for both BDQ and 
DLM respectively. The method reliably eliminated interfering 
materials from plasma, yielding a recovery for BDQ and DLM that 
ranged from 101% to 107% for DLM and 98 to 107 % for BDQ 
respectively (table 4). Stability values were defined in terms of 
changes in concentration and should be<15%. BDQ and DLM 
concentrations were stable in plasma at–20 °C up to one month. 
  

















5 10 7.5 7.68 102 10 7.5 7.76 103 
1 5 3 3.11 104 5 3 2.95 98 
0.5 1 0.75 0.76 101 1 0.75 0.76 101 
0.05 0.1 0.075 0.08 107 0.1 0.075 0.08 107 
µg/ml = microgram per millilitre 
 
Clinical application 
The method described was applied for the determination of BDQ 
and DLM concentrations in plasma samples from 5 patients who 
were on treatment for XDR-TB receiving 200 mg BDQ once daily and 
100 mg DLM bi-daily under the BEAT study (fig. 3). Serial blood 
samples were collected at different time points after drug 
administration. The mean plasma peak concentration of BDQ and 
DLM were 3.29 µg/ml and 0.34 µg/ml respectively. 
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Fig. 3: Plasma bedaquiline and delamanid concentration-time curve 
 
DISCUSSION 
This report describes the design and validation of a simple, specific 
and sensitive simultaneous analysis method using high-performance 
liquid chromatography for the determination of BDQ and DLM 
concentrations in plasma. The method developed showed good 
accuracy and precision. The calibration curve was linear ranging 
from 0.01 to 10.0 µg/ml for both BDQ and DLM respectively. The 
assay spans the concentration range of clinical interest.  
Many methods are available that can quantitate plasma BDQ and 
DLM by LCMS/MS [2, 6, 7]. Meng et al. developed a method to 
quantitate DLM and its metabolites in plasma using UHPLC-MS/MS 
[7]. These expensive techniques are out of reach for several 
laboratories with resource-poor settings. None of the LCMS/MS 
methods included second-line anti-TB or anti-retroviral drugs in 
their specificity experiments. Treatment of MDR-TB is always a 
combination of second-line anti-TB drugs. The available LCMS/MS 
methods estimate BDQ or DLM separately. The developed HPLC 
method quantitates both BDQ and DLM simultaneously.  
As an evaluation of drug concentrations in relation to the 
susceptibility of the pathogen may help to explain differences in 
treatment responses, it is highly desirable that pharmacokinetics 
should become part of future phase III studies [9]. Therefore 
estimation of plasma drug concentrations of new drugs such as BDQ 
and DLM will receive more attention in future pharmacokinetic 
studies and therapeutic drug monitoring. 
CONCLUSION  
In conclusion, we have described a simultaneous method for 
estimation of BDQ and DLM in plasma, that has the sensitivity to 
quantitate these drugs from 0.01 µg/ml which is sufficiently enough 
for future pharmacokinetic studies. This method is reproducible and 
specific for the determination of BDQ and DLM in human plasma, 
yielding satisfactory recovery from human plasma. Stability 
experiments showed that BDQ and DLM were stable up to 30 d when 
stored at-20 °C. This method could be used in clinical studies 
evaluating drug exposure and correlating with treatment outcome. 
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